Turing Medical

Turing Medical is a precision brain mapping and neuromodulation therapy company. The company develops PACE (Personalized Adaptive Cortical Electro-Stimulation), a precision-guided neuromodulation therapy platform designed to treat severe depression and chronic pain through adaptive cortical stimulation. PACE combines precision functional mapping with cortical stimulation, intended to restore healthy brain activity without the invasiveness of deep brain surgery—analogous to how a pacemaker restores cardiac rhythm. The company was formerly known as Nous Imaging and is led by co-founders Nico Dosenbach, M.D., PhD and Damien Fair, PA-C, PhD, both neuroscience researchers with published work in Nature on brain plasticity and precision functional mapping. Turing Medical's research focuses on reproducible brain-wide association studies, precision dynamical mapping, and mind-body network discovery. The company has appointed Kevin King, a medtech executive with three decades of experience in precision medicine and diagnostic technologies, as President and CEO as of April 2025, signaling expansion into clinical applications and commercialization. Turing Medical serves the neurology, psychiatry, and pain management markets. The company's technology platform leverages advanced functional brain imaging and mapping capabilities to enable personalized treatment targeting.